Is Evening Primrose Oil Worth It for Menopause? What the Evidence Shows

The short answer

For hot flushes and night sweats, evening primrose oil (EPO) is not worth your money on the evidence we have. The trials are small, short and inconsistent, and the better-designed ones are negative. The 2023 nonhormone therapy position statement of The Menopause Society (then NAMS) does not recommend supplements and herbal remedies for vasomotor symptoms — EPO included — because the evidence does not support them.

That is the verdict, stated plainly. But "it doesn't work" is only half a useful article. Below is what EPO was supposed to do, what the trials actually found, why hot-flush research is unusually good at producing false positives, the one indication where EPO has a longer (though still unimpressive) history, the interaction that genuinely matters, and — most importantly — what does have evidence, so you leave with a plan rather than a debunking.

What is evening primrose oil, and what is it supposed to do?

Evening primrose oil is pressed from the seeds of Oenothera biennis, a North American wildflower. Its selling point is gamma-linolenic acid (GLA), an omega-6 fatty acid that makes up roughly 8–10% of the oil. Most dietary omega-6 arrives as linoleic acid, which the body must convert to GLA using an enzyme (delta-6-desaturase) before it can be elongated to dihomo-gamma-linolenic acid and turned into prostaglandin E1 — a signalling molecule with anti-inflammatory and vasodilatory effects.

The theory, popularised in the 1980s, was that some people convert linoleic acid to GLA inefficiently, and that supplying GLA directly could restore prostaglandin balance. Applied to menopause, the claim mutated into something vaguer: that EPO "balances hormones" or steadies the vascular instability behind a hot flush. It is worth being precise here — EPO contains no hormones, is not a phytoestrogen, and does not raise oestrogen. Whatever it does, it is not hormone replacement, and marketing that implies otherwise is wrong.

The mechanism is plausible. Plausible mechanisms are cheap. The question is whether it does anything in a trial.

What did the hot-flush trials actually find?

The honest summary: a handful of small trials, mostly under 100 women, mostly six weeks to six months long, using different doses and different symptom scales, producing contradictory results.

The reference point is still Chenoy and colleagues (BMJ, 1994): 56 women with at least three flushes a day, randomised to gamolenic acid from evening primrose oil (with vitamin E) or placebo for six months — though only 35 of them finished. Result: gamolenic acid offered no benefit over placebo for menopausal flushing. The one difference that reached statistical significance was a small reduction in the maximum number of night-time flushes, which the authors did not treat as evidence of a useful effect.

Thirty years on, the picture has not improved. A 2024 systematic review and meta-analysis in the Journal of Menopausal Medicine (Thevi, De and Soe) pooled four randomised controlled trials and found no significant difference between EPO and placebo in the frequency of daytime flushes (P = 0.62), night-time flushes (P = 0.64) or their duration (P = 0.83). Severity was lower with EPO in trials shorter than six months (P = 0.004) — a single, fragile finding that did not hold at six months or beyond (P = 0.38), was not accompanied by any change in how often flushes occurred, and rests on a tiny evidence base. In a head-to-head comparison, EPO came off worse than black cohosh on severity at eight weeks. The authors' own conclusion: there is currently insufficient evidence to say EPO helps hot flushes.

The most-cited "positive" study is a six-week Iranian randomised trial in 56 women (Farzaneh and colleagues, Archives of Gynecology and Obstetrics, 2013), one of the four pooled above. Look at its numbers rather than its headline: hot-flush frequency fell 39% on EPO versus 32% on placebo — a difference that was not statistically significant — and duration fell 19% versus 18%. Only severity separated the groups (42% versus 32%). A supplement that changes how bad a flush feels but not how often it comes, in 56 women over six weeks, is the shape of a weak signal, not a treatment.

Why do weak studies of hot-flush remedies keep looking positive?

This is the single most important thing to understand about the entire menopause supplement aisle, and it is why we grade the evidence rather than repeating headlines.

Hot flushes have an enormous placebo response. In pooled data from the MsFLASH research network, women randomised to placebo cut their hot flushes by about 30% — and a third of them met the usual clinical bar of a 50% or greater reduction by week eight. The improvement built gradually, week on week, exactly the way a real drug effect builds. In the Cochrane review of oral hormone therapy, placebo arms did better still: a 57.7% reduction in flushes from baseline to end of study. The Cochrane authors drew the obvious moral — because the placebo effect is this large, and because symptoms fluctuate and eventually decline on their own, any therapy claiming to reduce flushes has to be tested blind against placebo.

Add three more forces. Hot flushes come in waves, so anyone who starts a supplement during a bad patch will improve regardless (regression to the mean). Symptom diaries change behaviour because the woman knows she is being watched. And people who spend money on a capsule are motivated to notice improvement.

Put it together: a small, unblinded or poorly controlled trial will show a "benefit" from almost anything. That is not fraud — it is arithmetic. It is precisely why a supplement can have hundreds of glowing reviews, a handful of positive-sounding small studies, and still be doing nothing at all.

Evidence grade at a glance

What about breast pain — isn't that what evening primrose oil is for?

This is the fairest question, and it deserves an honest answer rather than a dismissal.

Cyclical mastalgia — breast pain that tracks the menstrual cycle — is where EPO earned its reputation, and where it was once an actual licensed medicine in the UK. Two GLA products held marketing authorisations: Epogam (atopic eczema) and Efamast (mastalgia). Then, with effect from 7 October 2002, the Medicines Control Agency (now the MHRA), acting on a Committee on Safety of Medicines review, withdrew those licences — not over safety, but because the available evidence did not meet the standard of efficacy required of a medicine. EPO did not simply fall out of fashion; it failed a regulatory review. Today it is sold in the UK as a food supplement, licensed for nothing.

Since then, the better trials have been unhelpful to EPO. Randomised studies comparing EPO (with or without vitamin E) against placebo in cyclical mastalgia have generally found pain falling in both arms with no convincing advantage for EPO. The US National Center for Complementary and Integrative Health puts it bluntly: evening primrose oil "is probably not more effective than a placebo" for breast pain.

So the signal here is somewhat better than for hot flushes — there is at least a coherent literature, and EPO is one of the few things ever formally trialled for mastalgia — but the direction of travel over 30 years has been from "promising" to "probably placebo". If breast pain is your problem, the more useful move is working out what kind of breast pain it is: start with breast pain causes and sore breasts in menopause, and get new, one-sided or persistent pain — and any lump — assessed rather than self-treated.

Is evening primrose oil safe? The interaction that actually matters

EPO is generally well tolerated. The commonest complaints in trials are mild and gastrointestinal: nausea, loose stools, stomach upset, headache. In the 2024 meta-analysis, side effects were not severe enough to make women stop taking it. That is the good news, and it is why EPO persists — it rarely hurts anyone, so nobody notices that it also rarely helps.

Two safety issues are worth taking seriously:

• Bleeding risk. EPO may increase the risk of bleeding, and that becomes clinically relevant if you take an anticoagulant (for example warfarin, apixaban, rivaroxaban) or an antiplatelet (aspirin, clopidogrel). It is also a reason to tell your surgeon and anaesthetist about it well ahead of any planned operation. If you take blood thinners, this is a conversation to have with the clinician who manages that prescription before adding EPO.
• Seizure threshold with phenothiazines. Taking EPO alongside phenothiazine antipsychotics has been linked to a raised risk of seizures. The reports are old and mostly involved people who already had a seizure history or abnormal EEGs, and phenothiazines lower the seizure threshold on their own — so the signal is soft. It is still worth flagging if you take a phenothiazine or have epilepsy.

EPO is also not a good idea in pregnancy without medical advice, and supplements in general are not tested against every drug you might be taking. If you are stacking several, run them through our interaction checker and take the list to your pharmacist.

None of this is a recommendation to start, stop or change anything. Decisions about supplements, hormone therapy and prescription medicines belong with your clinician, who knows your history.

What actually works for hot flushes?

If you found this page because flushes are wrecking your sleep and your working day, here is where the evidence is genuinely strong — so you can spend your effort on things that move the needle. The point of listing them is to route you to a conversation with a clinician, not to tell you what to take.

• Hormone therapy remains the most effective treatment for vasomotor symptoms: the Cochrane review found about a 75% reduction in flush frequency relative to placebo. Whether it suits you depends on your age, your time since menopause and your personal and family history. Start with our guide to hormone replacement therapy and pills vs patches vs gels.
• Fezolinetant, a non-hormonal drug that blocks the NK3 receptor in the brain's temperature-control centre, is approved for moderate-to-severe hot flushes and carries Level I evidence — alongside a boxed warning for rare but serious liver injury and label-mandated liver blood tests. See fezolinetant explained and how it compares with HRT.
• SSRIs and SNRIs — low-dose paroxetine, venlafaxine, escitalopram — reduce flushes and are recommended when hormones aren't suitable. See HRT vs antidepressants.
• CBT and clinical hypnosis are recommended (Level I) non-drug approaches. They change how much flushes bother you and how much they disrupt your life — an outcome that matters more than a diary count.
• Other prescription options — gabapentin (Level I) and oxybutynin — are also recommended in the 2023 statement. Our non-hormonal treatment guide and side-by-side comparison lay them out.

If you are not sure how bad your symptoms are in clinical terms, our menopause symptom score produces a number you can take to an appointment, and the doctor report tool turns it into something a clinician can act on.

When to talk to your clinician

Book an appointment — rather than self-treating with supplements — if any of the following apply:

• Your hot flushes or night sweats are disrupting sleep, work, mood or relationships. This is a treatable medical symptom, not a character test.
• You take an anticoagulant or antiplatelet, or a phenothiazine, or you have epilepsy, and you are considering evening primrose oil or any other supplement.
• You have surgery planned in the coming weeks and take EPO, fish oil or any other supplement that can affect bleeding.
• You have new breast pain in one breast, a lump, a skin or nipple change, or nipple discharge. These need assessment, not evening primrose oil.
• You have any bleeding after menopause, or new heavy or irregular bleeding in perimenopause. See postmenopausal bleeding — this is always worth a prompt appointment.
• You have taken a supplement for 8–12 weeks and nothing has changed. That is your answer; ask about the options that have evidence behind them.

Bring a list of everything you take, supplements included. Most people never mention supplements to their doctor, and interactions get missed for exactly that reason.

The bottom line

Evening primrose oil is safe for most people, cheap-ish, and almost certainly not doing what the label implies. For hot flushes, the trials are small, short and contradictory; the pooled analysis shows no effect on how often flushes happen or how long they last; and the placebo response in this field is large enough to explain every positive result on its own. For cyclical breast pain the literature is better developed but still points to placebo — and a UK regulator revoked its medicine licence for that very reason.

If you want to try it anyway, and you don't take blood thinners, the downside is mostly your wallet. But give it a fixed trial window, judge it honestly, and don't let it delay a conversation about treatments that are proven to work. If you're weighing up other supplements marketed for this life stage, we've graded the rest in the best supplements for menopause, and looked hard at two of the biggest sellers in black cohosh and soy and phytoestrogens.